A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The objective of this double-blind, placebo-controlled, multicentre randomized withdrawal study was to evaluate the efficacy and tolerability of sertraline for 16 weeks in treating Japanese patients with major depressive disorder (MDD) who had achieved a response to 8 weeks of sertraline treatment. Patients (n=361) were initially treated with 8 weeks of open-label sertraline treatment followed by 16 weeks of double-blind treatment with either sertraline (50-100 mg/day) or placebo. Responders during the open-label phase were eligible to be entered into the double-blind phase. A total of 235 patients (65.1%) were entered to the double-blind phase and randomly assigned to receive sertraline (n=117) or placebo (n=118). A significantly (P=0.016) lower relapse rate was found for sertraline (8.5%) compared to placebo (19.5%) during the double-blind phase. Examination of time-to-relapse showed that the relapse free rate curve was significantly higher for sertraline (log-rank test, P=0.026) than placebo. Mean changes from beginning to end of the double-blind phase on measure of depressive symptoms, quality of life and global improvement also significantly favoured sertraline over placebo. Sertraline was well-tolerated, with similar adverse events as found in previous studies. These results confirm the efficacy of sertraline in preventing the relapse of MDD in Japanese patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Escitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121
Robert, P., Montgomery, S. A., Darcourt, G., Robert, G., Houillon, P., Bouchard, J. M., Tatossian, A., Planche, R., Bourgeois, M., Richou, H., et al. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199503001-00006 · Cited by 85
Research works printed but not linked: 24
- berg-Wistedt, 2000, Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy, J Clin Psychopharmacol, 20, 645, 10.1097/00004714-200012000-00010 · DOI · Paper page
- Brown, 1995, Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another?, J Clin Psychiatry, 56, 30
- Doogan, 1992, Sertraline in the prevention of depression, Br J Psychiatry, 160, 217, 10.1192/bjp.160.2.217 · DOI · Paper page
- Endicott, 1993, Quality of Life, Enjoyment, and Satisfaction Questionnaire: a new measure, Psychopharmacol Bull, 29, 321
- Fabre, 1995, Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo, Biol Psychiatry, 38, 592, 10.1016/0006-3223(95)00178-8 · DOI · Paper page
- Fava, 2002, Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia, J Clin Psychopharmacol, 22, 137, 10.1097/00004714-200204000-00006 · DOI · Paper page
- Froom, 1995, Depressive disorders in three primary care populations: United States, Israel, Japan, Family Pract, 12, 274, 10.1093/fampra/12.3.274 · doi:10.1093/fampra/12.3.274
- Hamilton, 1967, Development of a rating scale for primary depressive illness, Br J Soc Clin Psychol, 6, 278, 10.1111/j.2044-8260.1967.tb00530.x · DOI · Paper page
- Jablensky, 1981, Characteristics of depressive patients contacting psychiatric services in four cultures, Acta Psychiatr Scand, 63, 367, 10.1111/j.1600-0447.1981.tb00685.x · DOI · Paper page
- Joffe, 1996, Response to an open trial of a second SSRI in major depression, J Clin Psychiatry, 57, 114
- Keller, 1998, Maintenance phase efficacy of sertraline for chronic depression. A randomized controlled trial, JAMA, 280, 1665, 10.1001/jama.280.19.1665 · DOI · Paper page
- Kessler, 2003, The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R), JAMA, 289, 3095, 10.1001/jama.289.23.3095 · DOI · Paper page
- Koran, 2001, Sertraline versus imipramine to prevent relapse in chronic depression, J Affect Disord, 65, 27, 10.1016/S0165-0327(00)00272-X · DOI
- Latimer, 1996, A six month comparison of toleration and efficacy of sertraline and fluoxetine treatment of major depression, Eur Neurophsychopharmacol, 6, 124, 10.1016/0924-977X(96)87876-X · doi:10.1016/0924-977x(96)87876-x
- Lydiard, 1997, A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression, J Clin Psychiatry, 58, 484, 10.4088/JCP.v58n1104 · DOI · Paper page
- Montgomery, 1993, Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression, Int Clin Psychopharmacol, 8, 189, 10.1097/00004850-199300830-00009 · DOI · Paper page
- Montgomery, 1993, A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression, Int Clin Psychopharmacol, 8, 181, 10.1097/00004850-199300830-00008 · DOI · Paper page
- Ohishi, 2002, A comparison of characteristics of depressed patients and efficacy of sertraline and amitriptyline between Japan and the West, J Affect Disord, 70, 165, 10.1016/S0165-0327(01)00340-8 · doi:10.1016/s0165-0327(01)00340-8
- Radford, 1989, A study of depression in two cultures: a transcultural study with Japanese and Australian clinically depressed patients, Jpn J Psychiatry Neurol, 43, 119
- Reimherr, 1998, Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment, Am J Psychiatry, 155, 1247, 10.1176/ajp.155.9.1247 · DOI · Paper page
- Reimherr, 1990, Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression, J Clin Psychiatry, 51, 18
- Thase, 1997, Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline, J Clin Psychiatry, 58, 16, 10.4088/JCP.v58n0103 · DOI · Paper page
- 2000, Cross-national comparisons of the prevalences and correlates of psychiatric disorders, Bull World Health Organ, 78, 413
- Zarate, 1996, Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline?, J Clin Psychiatry, 57, 67
Cited by
Bradley, A. J., & Dinan, T. G. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810385491 · Cited by 256
Andrews, P. W., Kornstein, S. G., Halberstadt, L. J., Gardner, C. O., & Neale, M. C. (2011) · Frontiers in Psychology · doi:10.3389/fpsyg.2011.00159 · Cited by 107
Braun, C., Bschor, T., Franklin, J., & Baethge, C. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000442293 · Cited by 103
Meta-analysis of relapse prevention antidepressant trials in depressive disorders
Glue, P., Donovan, M. R., Kolluri, S., & Emir, B. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048671003705441 · Cited by 100
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Metadata
- Authors
- Kamijima, K., Burt, T., Cohen, G., Arano, I., & Hamasaki, T.
- Venue
- International Clinical Psychopharmacology
- Published
- 2006-01
- Volume
- 21
- Issue
- 1
- Pages
- 1-9
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2069685073
- Cited by
- 31
- References
- 2
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan. https://app.cochat.ai/papers/10.1097/01.yic.0000182118.57510.d1
- The paper
- Kamijima, K., Burt, T., Cohen, G., Arano, I., & Hamasaki, T. (2006). A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan. International Clinical Psychopharmacology. https://doi.org/10.1097/01.yic.0000182118.57510.d1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.